SEC filing · 8-K

Kyntra Bio, Inc.: Executive or director change

Kyntra Bio appointed Andrew E. Singer to its board of directors, announced the resignation of Maykin Ho, and renewed its severance agreement with CEO Thane Wettig.

Filed October 1, 2026

Neutral news

What happened

Andrew E. Singer was appointed as a Class III director and Audit Committee member effective October 1, 2026, with a term expiring in 2029.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Kyntra Bio, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.